Automating Non-Viral Cell Therapy Manufacturing: Cocoon® Meets Nucleofector®

Published on Lonza White Paper (CT-SP008)

Cell therapy manufacturing is often held back by viral vector limitations and labor-intensive workflows. This white paper from Lonza introduces a fully closed, automated non-viral workflow that integrates the 4D-Nucleofector® LV Unit with the Cocoon® Platform. Using this system, researchers successfully transfected primary T cells and expanded them over 10 days with consistent viability (>97%), purity (>90% CD3+), and clinically relevant cell yields (~2.8 billion cells). The process shows promise for streamlining non-viral CAR-T manufacturing, reducing cost, time, and manual error.

Read the full white paper on Lonza:

👉 Cocoon Platform and Nucleofector Technology for Non-Viral Workflow (PDF)

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.